Aptorum Group Limited (NASDAQ:APM) Short Interest Down 38.5% in June

Posted by Brian Himes on Jul 17th, 2026

Aptorum Group Limited (NASDAQ:APM – Get Free Report) was the target of a large decline in short interest in June. As of June 30th, there was short interest totaling 62,491 shares, a decline of 38.5% from the June 15th total of 101,658 shares. Currently, 2.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 42,111 shares, the days-to-cover ratio is currently 1.5 days.

Aptorum Group Stock Up 3.7%

NASDAQ APM traded up $0.03 on Friday, hitting $0.72. 17,243 shares of the company were exchanged, compared to its average volume of 96,678. Aptorum Group has a 1-year low of $0.61 and a 1-year high of $4.47. The firm has a 50 day moving average of $0.86 and a two-hundred day moving average of $0.89.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of Aptorum Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Get Our Latest Report on Aptorum Group

About Aptorum Group

(Get Free Report)

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.